10-Q 2026-07-30 ↗ compared with the reference 10-K 10-K 2026-02-12 ↗
Technical events and factor profile →
Alnylam Pharmaceuticals warns of potential revenue impact from competitors' products and Medicare reimbursement changes. Among the new risks: competitors' Products May Reduce Alnylam's Revenue Potential and medicare Reimbursement Changes Threaten Alnylam's Product Demand.
| After the 10-Q | 1 session | 5 sessions | 20 sessions |
|---|---|---|---|
| ALNY | -28.3% | -20.2% | -16.6% |
| Nasdaq-100 (QQQ) | +3.3% | +8.4% | +7.5% |
| Difference | -31.6% | -28.6% | -24.1% |
From the close before the filing. Historical data, not a prediction.
Positive or negative safety or efficacy developments with competitive products or product candidates may impact revenue from AMVUTTRA and the commercial potential of any other products for which we receive regulatory approval for the treatment of ATTR amyloidosis with cardiomyopathy. In July 2026, for example, Ionis and AstraZeneca announced topline results from their Phase 3 CARDIO-TTRansform trial of eplontersen in patients with ATTR amyloidosis with cardiomyopathy, reporting that the trial did not meet its primary endpoint of reducing cardiovascular mortality and recurrent cardiovascular events and did not demonstrate a statistically significant benefit in a contemporary patient population in which a majority of patients were treated with a TTR stabilizer. The full data set from the CARDIO-TTRansform clinical trial, when released, may influence physicians’ prescribing patterns, which may impact demand for AMVUTTRA and any other products for which we receive regulatory approval for the treatment of ATTR amyloidosis with cardiomyopathy, affecting our revenue.
| Jun 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.1B | $1.2B | $774M | $594M |
| YoY growth | +66.9% | +84.9% | +149.3% | +17.3% | +20.2% |
| Gross margin | — | — | — | — | — |
| Operating margin | 17.9% | 12.0% | 29.5% | -2.1% | 3.0% |
| Net income | $164M | $153M | $251M | -$72M | -$18M |
| Diluted EPS | 1.21 | 1.18 | 1.84 | -0.55 | -0.14 |
XBRL data filed with the SEC. The fourth fiscal quarter is calculated as the full year minus the previous three quarters.
0 = the lowest in the universe, 100 = the highest. It describes how the stock has behaved, not whether to buy or sell it. Screen stocks by factors
Similar than in the previous 10-Q (2026-04-30: +26, +1 points)
10-Q of 2026-07-30 · 34.2% positive sentences, 5.5% negative · 199 sentences analysed
Index from −100 to +100 calculated with FinBERT on the results discussion (MD&A). The change matters more than the level: some sectors always sound more cautious.
| Bridgewater Associates · Ray Dalio
held since Q3 2025 |
0.1% | $30.0M | -7% |
Weight in each fund's portfolio and change vs. the previous quarter, from its latest 13F.
All material events for ALNY →
| 2026-10-02 | SUPRAN BRYAN · Officer | Sell | $399K | SEC ↗ |
Source: SEC EDGAR. Automatic comparison of the risk factors section; it may contain extraction errors. Always check the original document. For information purposes only; not investment advice.